Alleviant’s Novel Heart Failure Tech Gets FDA Breakthrough Designation
Alleviant Medical received FDA approval to begin a pivotal trial of its no-implant atrial shunt for heart failure patients...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Alleviant Medical received FDA approval to begin a pivotal trial of its no-implant atrial shunt for heart failure patients...
Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study,...
MAIA Biotechnology will collaborate with BeiGene to evaluate THIO, MAIA’s telomere-targeting anticancer drug, in combination with BeiGene’s immune checkpoint...
The global retinal gene therapy market is projected to exceed US$110 million in revenue in 2024, driven by the...
BioSkryb Genomics launched ResolveSEQ MRD, a service that enhances the analysis of minimal residual disease (MRD) in hematological malignancies....
Tenvie Therapeutics launched with $200 million in funding to develop small molecule treatments for neurological diseases. The company acquired...
The sales of the top 20 drugs targeting molecular switches have exceeded $30 billion, highlighting the growing importance of...
Quanta Therapeutics announced advancements in its KRAS-directed drug candidates, including FDA IND clearance for QTX3544, a G12V-preferring multi-KRAS inhibitor,...
AerWave Medical completed its first-in-human feasibility study of a novel ultrasound lung denervation therapy for chronic obstructive pulmonary disease...
Bitterroot Bio announced positive Phase 1 results for BRB-002, a first-in-class immune-modulating protein therapy targeting CD47 for atherosclerotic cardiovascular...